Navigation Links
SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma
Date:9/10/2007

TAMPA, Fla.September 10, 2007--Accentia Biopharmaceuticals (NASDAQ: ABPI) announces evidence that most, if not all cases of chronic sinusitis (CS), are due to a fungal-induced inflammation as originally proposed by investigators at the Mayo Clinic. The data were collected as part of the Companys ongoing pivotal Phase 3 clinical trial for its lead pharmaceutical product, SinuNase, an intranasal formulation of the antifungal amphotericin B 0.01% suspension. In order to be enrolled in the clinical trial, patients must have had well-documented CS based on a history of the requisite symptoms, nasal endoscopy findings, and CT scan demonstrating characteristic mucosal changes in the sinuses. At the time of enrollment, all patients have had nasal mucin collected. Subsequently, these specimens are being tested for eosinophilic major basic protein (eMBP). In the first fifty specimens now analyzed, all have been positive for eMBP, a toxic protein released by inflammatory cells in response to fungi. The Company believes that these findings strongly support a fungal-induced inflammation as the cause of CS.

SinuTest, the diagnostic used to measure eMBP in the nasal mucin, is a patented technology developed at the Mayo Foundation for Medical Education and Research. The technology is exclusively licensed to IMMCO Diagnostics, which has an exclusive commercialization agreement with Accentia Biopharmaceuticals. The Company believes that SinuTest will be a useful adjunct for identification of patients who are suspected of having CS and who may be candidates for treatment with SinuNase, assuming FDA approval.

As previously announced, Accentia has received Fast Track status from the Food and Drug Administration (FDA) for SinuNase, and it is conducting a randomized, double-blind, placebo-controlled Phase 3 clinical trial with severe CS patients at more than 50 sites across the U.S. To the knowledge of the Company, this is the first and only Phase 3 clinica
'/>"/>

Contact: Adam Holdsworth
aholdsworth@investorrelationsgroup.com
212-825-3210
The Investor Relations Group
Source:Eurekalert

Page: 1 2

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. Worlds largest rainforest drying experiment completes first phase
3. Kinovate Life Sciences Launches Nittophase?High Performance Solid Support For Oligonucleatide Synthesis
4. Expression Project for Oncology (expO) completes first phase of standardized gene expression analyses
5. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer
6. Ebola DNA vaccine produces immune responses in all fully vaccinated volunteers in Phase 1 trial
7. NIH announces phase III clinical trial of creatine for Parkinsons disease
8. Farm kids almost twice as likely to die from injury as children overall
9. Chronic pain up almost 40 percent among US workers in past decade
10. Hunger in America rises by 43 percent over last five years
11. Method slashes quantum dot costs by 80 percent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2015)... Aug. 17, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... campaign for Q4 2015. The new marketing campaign is ... of Amplitude Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ... a leader in retail driven marketing and brand awareness ...
(Date:8/11/2015)... GOTHENBURG, Sweden , August 11, 2015 ... sensor FPC1155. Already received as well as expected revenues in 2015 ... included in FPC,s communicated revenue guidance of approximately 2,200 MSEK for ... is a prominent smartphone manufacturer ... ZUK selected FPC1 155 ...
(Date:8/6/2015)... JOSE, Calif. , Aug. 6, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... TouchPad technologies on Windows 10. Microsoft leveraged Synaptics, ... to the operating system. Through ... drivers are fully certified with Microsoft,s Precision TouchPad ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... Jr., M.D., one of the "fathers" of the ... receive the seventh annual American Association for Cancer ... Cancer Prevention Research. The award is given ... the field of cancer prevention research in basic, ...
... National Jewish Health have identified a simple gene-based blood ... patients, response to therapy than current tests. The test, ... care and help clear a backlog of promising medications ... published the results of a small "proof-of-principal" trial in ...
... Signal Patterns, SP Labs Election Patterns Report explains ... of voters; report also,reveals that openness and conscientiousness ... findings, PLEASANTVILLE, N.Y., Oct. 23 SP ... of scientific-based social web,applications that characterize and connect ...
Cached Biology News:Meyskens honored with AACR-Prevent Cancer Foundation award 2New test promises quicker, more accurate evaluation for cystic fibrosis patients 2New test promises quicker, more accurate evaluation for cystic fibrosis patients 3New Study Reveals the Emotional Impact and Effectiveness of Negative Campaigning 2New Study Reveals the Emotional Impact and Effectiveness of Negative Campaigning 3New Study Reveals the Emotional Impact and Effectiveness of Negative Campaigning 4
(Date:9/2/2015)... and LIBERTYVILLE, Ill. (PRWEB) , ... ... ... International, a leading provider of regulatory compliance, quality systems, analytical testing, education ... a consulting firm with expertise in medical device products/processes development, design control, ...
(Date:9/2/2015)... -- Research and Markets ( ... PharmaBiotech,s new report "Biomarkers - Technologies, Markets ... This report follows the broad definition of a ... measured and evaluated as an indicator of normal ... responses to a therapeutic intervention. Tests based on ...
(Date:9/2/2015)... ... September 02, 2015 , ... Drug companies increasingly are ... BCC Research reveals in its new report that the U.S. will generate the ... and generates the most market demand. , BCC Research examines plant-derived drugs ...
(Date:9/2/2015)... 2015 Veracyte, Inc. (NASDAQ: VCYT ) ... and chief executive officer, will present at the Morgan ... at 10:30 a.m. ET in New York, ... webcast and subsequent replay may be accessed by visiting Veracyte,s website ... shortly after conclusion of the presentation and archived on ...
Breaking Biology Technology:NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Veracyte to Present at Morgan Stanley Global Healthcare Conference 2
... May 1 /PRNewswire-Asia/ -- Yongye Biotechnology International, Inc. (OTC ... distributor of plant and animal nutrient products located in ... of the independently owned Yongye branded retail stores in ... day sales.A Yongye branded retail store in Qianjiang City ...
... SAN DIEGO, May 1 BioMed Realty Trust, Inc. ... has entered into a new 15-year lease with Regeneron ... Landmark at Eastview campus in Tarrytown, New York, which ... lease expansion, Alan D. Gold, BioMed,s Chairman and Chief ...
... Held on May 15, 2009 at 8:00 am (Eastern) ... May 1 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: ... medical device R&D outsourcing company with operations in China ... release financial results for the first quarter of 2009 ...
Cached Biology Technology:Yongye Biotechnology Distributor has Record Breaking Single Store Sales Day 2Yongye Biotechnology Distributor has Record Breaking Single Store Sales Day 3BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals 2BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals 3WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release 2
... intended for use as a wash buffer for ... Fluid is useful for transportation of specimens (such ... studies. Samples may remain in Transport Fluid ... Michels Transport Fluid is not a fixative ...
... with 96- or 384-well PCR plates Dimples on ... on 96-tube plates End tabs on Thermo-Mat™ 384 ... Efficient sealing is achieved with either Thermo-Mat™ 96 ... clip-down hot lid thermal cyclers Fully autoclavable ...
... The TUNEL-based assay kit provides complete components ... convenient detection of DNA fragmentation in cultured ... BrdU in the procedure provides greater sensitivity ... be analyzed by flow cytometry. The kit ...
... is a unique alternative to traditional ... acetate-EDTA) electrophoresis buffers. Bionic Buffer allows ... running times, and high-resolution band separation. ... electrophoresis after dilution to working 1x ...
Biology Products: